A phase II clinical trial investigating TMZ plus CMV pp65-LAMP mRNA-pulsed DCs administered with GM-CSF and tetanus-diphtheria toxoid is ongoing in patients with newly diagnosed GBM (NCT02465268) (80). The gene discussed is CSF2; the disease is glioblastoma.